TISIDB

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF00038 Intermediate filament protein
Function	Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair (By similarity). Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state (By similarity). Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway (By similarity). Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial "stem cells". Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors (By similarity). May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0001942 hair follicle development GO:0006417 regulation of translation GO:0008544 epidermis development GO:0009913 epidermal cell differentiation GO:0010608 posttranscriptional regulation of gene expression GO:0016049 cell growth GO:0022404 molting cycle process GO:0022405 hair cycle process GO:0030216 keratinocyte differentiation GO:0030307 positive regulation of cell growth GO:0031069 hair follicle morphogenesis GO:0031424 keratinization GO:0034248 regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0042303 molting cycle GO:0042633 hair cycle GO:0042634 regulation of hair cycle GO:0042635 positive regulation of hair cycle GO:0043588 skin development GO:0045103 intermediate filament-based process GO:0045104 intermediate filament cytoskeleton organization GO:0045109 intermediate filament organization GO:0045682 regulation of epidermis development GO:0045684 positive regulation of epidermis development GO:0045727 positive regulation of translation GO:0045927 positive regulation of growth GO:0048730 epidermis morphogenesis GO:0051797 regulation of hair follicle development GO:0051798 positive regulation of hair follicle development GO:0098773 skin epidermis development
Molecular Function	GO:0005200 structural constituent of cytoskeleton GO:0032395 MHC class II receptor activity GO:0042287 MHC protein binding GO:0042289 MHC class II protein binding
Cellular Component	GO:0005882 intermediate filament GO:0045111 intermediate filament cytoskeleton

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1266738: Developmental Biology R-HSA-6805567: Keratinization

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KRT17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between KRT17 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
20871598	Skin Basal Cell Carcinoma	Inhibit immunity (T cell function)	We here show that genetic ablation of keratin 17 (Krt17) protein, which is induced in basaloid skin tumors and co-polymerizes with Krt5 in vivo, delays basaloid follicular hamartoma tumor initiation and growth in mice with constitutive Hh signaling in epidermis. This delay is preceded by a reduced inflammation and a polarization of inflammatory cytokines from a Th1- and Th17-dominated profile to a Th2-dominated profile. Re-expression of Krt17 in Gli2(tg); Krt17(-/-) keratinocytes induces select Th1 chemokines that have established roles in BCC.

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KRT17 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KRT17 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.944	0.355
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.745	0.659
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	2.195	0.103
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.236	0.739
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.218	0.943
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.815	0.827
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-1.452	0.211
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-2.46	0.141
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.457	0.795
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.86	0.429
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.114	0.935
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.582	0.06

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KRT17 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KRT17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KRT17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KRT17. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KRT17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KRT17 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KRT17 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KRT17
Name	keratin 17, type I
Aliases	PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location	17q21.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KRT17 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KRT17